Severe Acute Respiratory Distress Syndrome during Infliximab Therapy in a Patient with Crohn Disease

Schoehl, Johanna; Mechie, Nicolae‐Catalin; Schwoerer, Harald; Moerer, Onnen; Quintel, Michael; Buck, Cordula; Ellenrieder, Volker; Neeße, Albrecht; Amanzada, Ahmad

doi:10.1159/000450676

Search citation statements

Order By: Relevance

Paper Sections

Select...

Infliximab and Rate Of Mechanical Ventilation In Covid-19 Pa...1

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2017

2024

Publication Types

Select...

Preprint1

Article1

Relationship

Self Cite0

Independent2

Authors

Journals

Cited by 2 publications

(1 citation statement)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Infliximab may potentially induce pulmonary complications like non-infectious interstitial lung disease and thereby should be cautiously prescribed in patients with SARS-CoV-2 [26].…”

Section: Infliximab and Rate Of Mechanical Ventilation In Covid-19 Pa...mentioning

confidence: 99%

Effects of Infliximab on patients with COVID-19: a systematic review and meta-analysis

Ataei,

Orandi,

Malekabad

et al. 2024

Preprint

View full text Add to dashboard Cite

Despite the control of the COVID-19 pandemic, it remains one of the main concerns of healthcare systems throughout the world. Inflammation and hyper-reactive immune system play an essential role in developing SARS-CoV-2 infection, particularly in immunocompromised patients. Infliximab, an anti-TNFα antibody that is used in autoimmune disorders, may exert an important role in alleviating inflammation and hyper-reactive immunity. In this systematic review and meta-analysis, we have concluded that Infliximab can significantly decrease the mortality rate in patients with COVID-19. Conversely, it did not have a significant effect on the rate of hospitalization, mechanical ventilation, and adverse events during SARS-CoV-2 infection. More studies on the influence of Infliximab on patients with COVID-19 are warranted.

show abstract

“…Infliximab may potentially induce pulmonary complications like non-infectious interstitial lung disease and thereby should be cautiously prescribed in patients with SARS-CoV-2 [26].…”

Section: Infliximab and Rate Of Mechanical Ventilation In Covid-19 Pa...mentioning

confidence: 99%

Effects of Infliximab on patients with COVID-19: a systematic review and meta-analysis

Ataei,

Orandi,

Malekabad

et al. 2024

Preprint

View full text Add to dashboard Cite

show abstract

Infliximab

2017

Reactions Weekly

View full text Add to dashboard Cite

Severe Acute Respiratory Distress Syndrome during Infliximab Therapy in a Patient with Crohn Disease

Cited by 2 publications

References 18 publications

Effects of Infliximab on patients with COVID-19: a systematic review and meta-analysis

Effects of Infliximab on patients with COVID-19: a systematic review and meta-analysis

Infliximab

Contact Info

Product

Resources

About